New directions coming up for a number of agents – who are the likely winners?

It’s nearly a decade since I was last in Copenhagen for a conference and oddly, it seems to be a venue signalling new directions are taking place for pipeline agents.

Last time around it was a watershed moment of sorts for the DDR niche with a raft of key data presented on PARP inhibitors in ovarian cancer.

This time around the focus is on a completely different niche and indication altogether!

Ahead of some key phase 2 and 3 clinical data coming up this month, here’s our latest conference preview with a look at what to expect and watch out for…

To learn more from our latest autoimmune commentary and get a heads up on key research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by